Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis

Circulation

Volumn 114, Issue 6, 2006, Pages 565-573

  Heymans, Stephane ^a,b   Pauschinger, Matthias ^d   De Palma, Armando ^c   Kallwellis Opara, Angela ^d   Rutschow, Susanne ^d   Swinnen, Melissa ^a   Vanhoutte, Davy ^b   Gao, Fangye ^b   Torpai, Raimund ^d   Baker, Andrew H ^e   Padalko, Elisabeth ^c   Neyts, Johan ^c   Schultheiss, Heinz Peter ^d   Van De Werf, Frans ^b   Carmeliet, Peter ^b   Pinto, Yigal M ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e WESTERN INFIRMARY   (United Kingdom)

Author keywords

Collagen; Metalloproteinases; Myocarditis; Pasminogen activators

Indexed keywords

COLLAGEN; MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS B3; CYTOKINE RELEASE; ECHOCARDIOGRAPHY; ENZYME INHIBITION; GENE DELETION; GENE INACTIVATION; GENE OVEREXPRESSION; HEART FAILURE; HEART INJURY; HEART PROTECTION; INFLAMMATORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS MYOCARDITIS;

ANIMALS; CYTOKINES; DILATATION, PATHOLOGIC; ENDOMYOCARDIAL FIBROSIS; ENTEROVIRUS B, HUMAN; ENTEROVIRUS INFECTIONS; FEMALE; GENE EXPRESSION REGULATION; HEART; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDITIS; MYOCARDIUM; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; URINARY PLASMINOGEN ACTIVATOR;

EID: 33746902380     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.591032     Document Type: Article

References (27)

1. Vallejo J, Mann DL. Antiinflammatory therapy in myocarditis. Curr Opin Cardiol. 2003;18:189-193.
2. Kearney MT, Cotton JM, Richardson PJ, Shah AM. Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management. Postgrad Med J. 2001;77:4-10.
3. McCarthy RE III, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, Baughman KL. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med. 2000;342:690-695.
4. Xiong D, Lee GH, Badorff C, Dorner A, Lee S, Wolf P, Knowlton KU. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. Nat Med. 2002;8:872-877.
5. Lee JK, Zaidi SH, Liu P, Dawood F, Cheah AY, Wen WH, Saiki Y, Rabinovitch M. A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis. Nat Med. 1998;4:1383-1391.
6. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. In: Nat Med. 1999;1135-1142.
7. Heymans S, Lupu F, Terclavers S, Vanwetswinkel B, Herbert JM, Baker A, Collen D, Carmeliet P, Moons L. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol. 2005;166:15-25.
8. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest. 2005;115:599-609.
9. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106:55-62.
10. Li J, Schwimmbeck PL, Tschope C, Leschka S, Husmann L, Rutschow S, Reichenbach F, Noutsias M, Kobalz U, Poller W, Spillmann F, Zeichhardt H, Schultheiss HP, Pauschinger M. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res. 2002;56:235-247.
11. Pauschinger M, Chandrasekharan K, Schultheiss HP. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system. Heart Fail Rev. 2004;9:21-31.
12. Padalko E, Verbeken E, De Clercq E, Neyts J. Inhibition of coxsackie B3 virus induced myocarditis in mice by 2-(3,4-dichlorophenoxy)-5- nitrobenzonitrile. J Med Virol. 2004;72:263-267.
13. Lane JR, Neumann DA, Lafond-Walker A, Herskowitz A, Rose NR. LPS promotes CB3-induced myocarditis in resistant B10.A mice. Cell Immunol. 1991;136:219-233.
14. Pauschinger M, Rutschow S, Chandrasekharan K, Westermann D, Weitz A, Peter Schwimmbeck L, Zeichhardt H, Poller W, Noutsias M, Li J, Schultheiss HP, Tschope C. Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response. Eur J Heart Fail. 2005;7:444-452.
15. Kim KS, Hufnagel G, Chapman NM, Tracy S. The group B coxsackieviruses and myocarditis. Rev Med Virol. 2001;11:355-368.
16. Schroen B, Heymans S, Sharma U, Blankesteijn WM, Pokharel S, Cleutjens JPM, Porter JG, Evelo CTA, Duisters R, van Leeuwen REW, Janssen BJA, Debets JJM, Smits JFM, Daemen MJAP, Crijns HJGM, Bornstein P, Pinto YM. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res. 2004;95:515-522.
17. Hashimoto I, Tatsumi M, Nakagawa M. The role of T lymphocytes in the pathogenesis of Coxsackie virus B3 heart disease. Br J Exp Pathol. 1983;64:497-504.
18. Kishimoto C, Hiraoka Y, Takada H. T cell-mediated immune response enhances the severity of myocarditis in secondary cardiotropic virus infection in mice. Basic Res Cardiol. 2001;96:439-445.
19. St-Pierre Y, Potworowski EF. T cell control of extracellular matrix degradation. Dev Immunol. 2000;7:171-177.
20. Gyetko MR, Chen GH, McDonald RA, Goodman R, Huffnagle GB, Wilkinson CC, Fuller JA, Toews GB. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans: a murine transgenic model. J Clin Invest. 1996;97:1818-1826.
21. Gyetko MR, Aizenberg D, Mayo-Bond L. Urokinase-deficient and urokinase receptor-deficient mice have impaired neutrophil antimicrobial activation in vitro. J Leukoc Biol. 2004;76:648-656.
22. Huber SA, Job LP. Cellular immune mechanisms in Coxsackievirus group B, type 3 induced myocarditis in Balb/C mice. Adv Exp Med Biol. 1983;161:491-508.
23. Gundersen D, Tran-Thang C, Sordat B, Mourali F, Ruegg C. Plasmin-induced proteolysis of tenascin-C: modulation by T lymphocyte-derived urokinase-type plasminogen activator and effect on T lymphocyte adhesion, activation, and cell clustering. J Immunol. 1997;158:1051-1060.
24. Vaday GG, Lider O. Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation. J Leukoc Biol. 2000;67:149-159.
25. 111In monoclonal antibody specific for tenascin-C. Circulation. 2002;106:1397-1402.
26. Kuznetsova SA, Roberts DD. Functional regulation of T lymphocytes by modulatory extracellular matrix proteins. Int J Biochem Cell Biol. 2004;36:1126-1134.
27. Spinale FG, Coker ML, Bond BR, Zellner JL. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res. 2000;46:225-238.